Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The effect of metformin on preventing long-term COVID-19 symptoms among low-risk adults has not been studied. The objective of this study was to Assess metformin compared with placebo during acute SARS-CoV-2 infection on the presence of COVID-19 symptoms 180 days later.
Methods: The ACTIV-6 platform evaluated repurposed medications for mild to moderate COVID-19. Between September 19, 2023 and May 1, 2024, 2983 outpatient adults ≥30 years with confirmed SARS-CoV-2 infection and ≥2 COVID-19 symptoms for ≤7 days were included from 90 sites. Participants were randomized to metformin (titrated to 1500 mg daily) or placebo for 14 days. Post-acute sequelae of SARS-CoV-2 or death (PASCD) was ascertained by asking whether participants had symptoms they attributed to COVID-19 on day 180. Secondary outcomes included clinician diagnosis of long COVID. For the primary outcome, the single-sided threshold for efficacy was 0.975.
Results: Among 2983 participants, the median age was 47 years (interquartile range [IQR] 38-57); 63% were female; 47% Hispanic/Latino; 83% reported ≥1 prior COVID-19 infections or SARS-CoV-2 vaccines. There were no deaths. Overall, 96 (3.2%) reported COVID-19 symptoms on day 90, 101 (3.4%) on day 120, and 79 (2.6%) on day 180. The covariate-adjusted risk of PASCD on day 180 was lower in the metformin group (-0.008; 95% credible interval [CrI] -0.022 to 0.006; posterior probability of efficacy [PPE] 0.83), compared with the placebo group with an adjusted risk ratio of 0.79 (95% CrI 0.474 to 1.230). The risk of clinician diagnosis of long COVID (secondary outcome) on day 180 was lower in the metformin group (-0.007; 95% CrI -0.015 to 0.001; PPE 0.96), with a relative risk of 0.495 (95% CrI 0.155 to 0.995).
Conclusions: The posterior probability of efficacy for metformin preventing the primary endpoint did not exceed the prespecified threshold of 0.975 for declaring efficacy. Secondary outcomes were numerically better with metformin.
Trial Registration: ClinicalTrials.gov ( NCT04885530 ).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363699 | PMC |
| http://dx.doi.org/10.1101/2025.08.08.25333305 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Characteristics, Radiological, and Outcomes of Mucormycosis: A 14-Year Retrospective Study From Southern China.
Mycoses
September 2025
Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Background: Mucormycosis is a rare, rapidly progressive fungal infection with a high mortality rate. However, clinical data of mucormycosis patients, especially those related to adverse outcomes in China, remain limited.
Objective: To enhance understanding of the clinical characteristics of different infection site mucormycosis and identify the factors associated with adverse outcomes.
Impact of dementia on outcomes in older patients with COVID-19: A nationwide inpatient sample analysis.
Australas J Ageing
September 2025
School of Nursing, Hungkuang University, Taichung, Taiwan.
Objective: Although existing evidence suggests a potential link between dementia and adverse outcomes in patients with COVID-19, a definitive relationship is uncertain. This study aimed to evaluate the impact of dementia on in-hospital outcomes of patients in the presence of COVID-19.
Methods: The US Nationwide Inpatient Sample (NIS) was searched for patients 65 years or older hospitalised for COVID-19 in 2020.
Nasal Cytology and Clinical Rhinology Support a Translational Integrative Neuroscience Perspective.
J Integr Neurosci
August 2025
Complex Operative Unit (UOC) Otolaryngology-Head and Neck Surgery, Ospedale San Camillo de Lellis, Azienda Sanitaria Locale (ASL) Rieti-Sapienza University, 02100 Rieti, Italy.
Nasal cytology is evolving into a promising tool for diagnosing neurological and psychiatric disorders, especially those such as Alzheimer's and Parkinson's diseases. Moreover, recent research has indicated that biomarkers differ greatly between samples taken before and after death. Nasal cytology might help to identify the early stages of cognitive decline.
View Article and Find Full Text PDFManagement of Severe Ulcerative Colitis with Ambulatory Intravenous Corticosteroids (MOSAIC): A Treatment Approach to Avoid Hospitalization in Immunocompromised Patients.
Crohns Colitis 360
July 2025
Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Introduction: Acute severe ulcerative colitis (ASUC) typically requires hospitalization for intravenous (IV) corticosteroid treatment and monitoring. In response to the need to reduce inpatient stays, especially during the COVID-19 pandemic, outpatient treatment models have gained interest. This study evaluated the feasibility, safety, and patient satisfaction of outpatient IV corticosteroid treatment for ASUC.
View Article and Find Full Text PDFAssociations Between Inflammatory and Catecholamine Markers and Clinical Outcomes in People with Post-Acute SARS-CoV-2 Infection.
Int J Gen Med
September 2025
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.
Purpose: The diagnosis of post-acute SARS-CoV-2 infection (PASC) is broad, referring to new or persistent health problems >four weeks after being infected with SARSCoV-2. The aim of this study was to determine whether cytokines, chemokines or catecholamine levels could specify the clinical condition.
Patients And Methods: Seventy-nine participants participated in person to study PASC.